{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457138656
| IUPAC_name = 1-methyl-2-((phenylthio)methyl)-3-carbethoxy-4-((dimethylamino)methyl)-5-hydroxy-6-bromindole
| image = Arbidol.svg
| image2 = Umifenovir ball-and-stick model.png
| width = 200

<!--Clinical data -->
| tradename = Arbidol
| pregnancy_category = C
| legal_status = [[Over-the-counter drug|OTC]] <small>RU</small>
| routes_of_administration = [[Wiktionary:oral|Oral]] ([[Capsule (pharmacy)|hard capsules]], [[Tablet (pharmacy)|tablets]])

<!--Pharmacokinetic data-->
| bioavailability = 40%
| metabolism = Hepatic
| elimination_half-life = 17–21 hours
| excretion = 40% excrete as unchanged umifenovir in feces (38,9%) and urine (0,12%)<ref>{{cite web|title=Full Prescribing Information: Arbidol® (umifenovir) film-coated tablets 50 and 100 mg: Corrections and Additions|url=http://grls.rosminzdrav.ru/InstrImgMZ.aspx?regNr=ЛСР-003900/07&page=2|website=State Register of Medicines|publisher=Open joint-stock company “Pharmstandard-Tomskchempharm”|accessdate=3 June 2015|language=Russian}}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 131707-23-8
| ATC_prefix = L03
| ATC_suffix = AX
| PubChem = 9958103
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = N/A
| ChEMBL = 1214598
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 116151
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 93M09WW4RU
| PDB_ligand = 75U

<!--Chemical data-->
| C=22 | H=28 | Br=1 | Cl=1 | N=2 | O=4 | S=1 
| molecular_weight = 531.89 g/mol
| smiles = CCOC(=O)c1c(n(c2c1c(c(c(c2)Br)O)CN(C)C)C)CSc3ccccc3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = KCFYEAOKVJSACF-UHFFFAOYSA-N
}}

'''Umifenovir'''<ref>[http://apps.who.int/medicinedocs/documents/s18407en/s18407en.pdf Recommended INN: List 65.], WHO Drug Information, Vol. 25, No. 1, 2011, page 91</ref> (trade name {{lang-ru|Арбидол}}, {{zh|c=阿比朵尔}}) is an [[Antiviral drug|antiviral]] treatment for [[influenza]] infection used in [[Russia]]<ref name="pmid19028526">{{cite journal |vauthors=Leneva IA, Russell RJ, Boriskin YS, Hay AJ |title=Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol |journal=Antiviral Res. |volume=81 |issue=2 |pages=132–40 |date=February 2009 |pmid=19028526 |doi=10.1016/j.antiviral.2008.10.009 |url=http://linkinghub.elsevier.com/retrieve/pii/S0166-3542(08)00431-2}}</ref> and [[China]]. The drug is manufactured by [[Pharmstandard]] ({{lang-ru|Фармстандарт}}). Although some Russian studies have shown it to be effective, it is not approved for use in Western countries.  Chemically, umifenovir features an [[indole]] core, functionalized at all but one positions with different substituents. The drug inhibits viral entry into target cells and also stimulates the immune response.

Umifenovir is manufactured and made available as both [[Tablet (pharmacy)|tablets]] and [[Capsule (pharmacy)|capsules]].

==Status==
Testing of umifenovir's efficacy has mainly occurred in China and Russia,<ref name=Leneva >{{cite journal |vauthors=Leneva IA, Fediakina IT, Gus'kova TA, Glushkov RG |year= 2005 |title=[Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A] |journal= Терапевтический Архив (Therapeutic Archive) |volume= 77 |issue= 8 |pages= 84–88 |publisher=ИЗДАТЕЛЬСТВО "МЕДИЦИНА" |location= Moscow, Russia |pmid=16206613 |url= http://arbidol.org/arbidol-2005-works-as-well.html |type=Russian translation |accessdate=2008-02-22}}</ref><ref>{{cite journal |vauthors=Wang MZ, Cai BQ, Li LY |title=[Efficacy and safety of arbidol in treatment of naturally acquired influenza] |language=Chinese |journal=Zhongguo Yi Xue Ke Xue Yuan Xue Bao |volume=26 |issue=3 |pages=289–93 |year=2004 |pmid=15266832 |display-authors=etal}}</ref> and it is well known in these two countries.<ref name="pmid18393857">{{cite journal |vauthors=Boriskin YS, Leneva IA, Pécheur EI, Polyak SJ |title=Arbidol: a broad-spectrum antiviral compound that blocks viral fusion |journal=Curr. Med. Chem. |volume=15 |issue=10 |pages=997–1005 |year=2008 |pmid=18393857 |doi= 10.2174/092986708784049658|url=http://www.bentham-direct.org/pages/content.php?CMC/2008/00000015/00000010/0006C.SGM}}</ref>

Some of the Russian tests showed the drug to be effective.<ref name = Leneva/>

==Mode of action==

===Biochemistry===
Umifenovir inhibits membrane fusion.<ref name="pmid19028526"/>  Umifenovir prevents contact between the virus and target host cells. Fusion between the [[viral capsid]] and the [[cell membrane]] of the target cell is inhibited. This prevents viral entry to the target cell, and therefore protects it from infection.<ref name="pmid16854226">{{cite journal |vauthors=Boriskin YS, Pécheur EI, Polyak SJ |title=Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection |journal=Virol. J. |volume=3 |pages=56 |year=2006 |pmid=16854226 |doi=10.1186/1743-422X-3-56 |url=http://www.virologyj.com/content/3//56 |pmc=1559594}}</ref>

Some evidence suggests that the drug's actions are more effective at preventing infections from [[RNA virus]]es than infections from [[DNA virus]]es.<ref name="pmid17497238">{{cite journal |vauthors=Shi L, Xiong H, He J |title=Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo |journal=Arch. Virol. |volume=152 |issue=8 |pages=1447–55 |year=2007 |pmid=17497238 |doi=10.1007/s00705-007-0974-5|display-authors=etal}}</ref>

As well as specific antiviral action against both [[influenza A]] and [[influenza B]] viruses, umifenovir exhibits modulatory effects on the immune system. The drug stimulates a [[humoral immune response]], induces [[interferon]]-production, and stimulates the [[phagocytosis|phagocytic]] function of [[macrophage]]s.<ref name="pmid10222830">{{cite journal |author1=Glushkov RG |author2=Gus'kova TA |author3=Krylova LIu |author4=Nikolaeva IS |title=[Mechanisms of arbidole's immunomodulating action] |language=Russian |journal=Vestn. Akad. Med. Nauk SSSR |issue=3 |pages=36–40 |year=1999 |pmid=10222830 }}</ref>

===Clinical application===
Umifenovir is used primarily as an [[influenza treatment#antiviral drigs|antiviral treatments for influenza]]. The drug has also been investigated as a candidate drug for treatment of [[hepatitis C]].<ref name="pmid17455911">{{cite journal |authors=Pécheur EI, Lavillette D, Alcaras F |display-authors=etal |title=Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol |journal=Biochemistry |volume=46 |issue=20 |pages=6050–9 |year=2007 |pmid=17455911 |doi=10.1021/bi700181j |pmc=2532706}}</ref>

A more recent study (published online as an accepted manuscript by the ''Journal of Virolog''y) by Pécheur et al. indicates that umifenovir also has ''in vitro'' effectiveness at preventing entry of [[Ebola virus|Ebolavirus]] Zaïre Kikwit, Tacaribe [[arenavirus]] and [[Kaposi's sarcoma-associated herpesvirus|human herpes virus 8]] into mammalian cell cultures, while confirming umifenovir's suppressive effect ''in vitro'' on [[Hepatitis B]] and [[poliovirus]] infection of mammalian cells when introduced either in advance of viral infection or during infection.<ref name="JVI.02077-15">{{cite journal |url=http://jvi.asm.org/content/early/2016/01/04/JVI.02077-15.full.pdf+html?sid=1cabbe49-4a25-4875-9d84-f88f4c3dc0b9 |title=The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses |authors=Pécheur EI, Borisevich V,  Hlafmann P |journal=Journal of Virology |date=January 2016 |volume=90 |issue= 6|pages=3086–92 |doi=10.1128/JVI.02077-15|pmid=26739045 |pmc=4810626 |display-authors=etal}}</ref>

==Side effects==
[[Adverse drug reaction|Side effects]] in children include sensitization to the drug. No known overdose cases have been reported and [[allergic reactions]] are limited to people with [[hypersensitivity]]. The {{LD50}} is more than 4 g/kg.<ref>http://www.vidal.ru/poisk_preparatov/arbidol.htm</ref>

== References ==
{{Reflist|2}}

== External links ==
* "Мастерлек" Pharmaceuticals, Moscow, Russia. Patent number № 2033157, Registry number № 003610/01.
* {{Ru icon}} [http://www.arbidol.ru/  Arbidol]
* [http://www.arbidol.org/  English published clinical studies and translations for Arbidol 1973&ndash;2016]

{{RNA antivirals}}
{{influenza}}

[[Category:Anti-influenza agents]]
[[Category:Anti-RNA virus drugs]]
[[Category:Indoles]]
[[Category:Organobromides]]
[[Category:Phenols]]
[[Category:Amines]]
[[Category:Thioethers]]
[[Category:Ethyl esters]]
[[Category:Russian drugs]]